このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Lotus Eye Hospital and Institute 将来の成長

Future 基準チェック /06

現在、 Lotus Eye Hospital and Instituteの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Healthcare 収益成長	25.7%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Jan 24

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 08

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Jul 15

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Apr 07

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Oct 08

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Sep 02

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Jun 17

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Mar 11

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Dec 30

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

Nov 20

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

Sep 21

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

Aug 27

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Aug 03

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

Jul 06

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Lotus Eye Hospital and Institute は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NSEI:LOTUSEYE - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2024	482	29	0	57	N/A
12/31/2023	485	35	N/A	N/A	N/A
9/30/2023	486	40	-1	57	N/A
6/30/2023	477	41	N/A	N/A	N/A
3/31/2023	470	41	13	44	N/A
12/31/2022	464	40	N/A	N/A	N/A
9/30/2022	459	42	13	69	N/A
6/30/2022	449	46	N/A	N/A	N/A
3/31/2022	389	30	-3	44	N/A
12/31/2021	389	36	N/A	N/A	N/A
9/30/2021	372	32	37	49	N/A
6/30/2021	335	20	N/A	N/A	N/A
3/31/2021	324	16	23	27	N/A
12/31/2020	300	-5	N/A	N/A	N/A
9/30/2020	301	-14	8	26	N/A
6/30/2020	335	-6	N/A	N/A	N/A
3/31/2020	406	11	26	50	N/A
12/31/2019	420	21	N/A	N/A	N/A
9/30/2019	415	20	N/A	N/A	N/A
6/30/2019	401	11	N/A	N/A	N/A
3/31/2019	384	7	-5	42	N/A
12/31/2018	382	7	N/A	N/A	N/A
9/30/2018	381	9	N/A	N/A	N/A
6/30/2018	384	14	N/A	N/A	N/A
3/31/2018	380	17	15	58	N/A
12/31/2017	373	8	N/A	N/A	N/A
9/30/2017	359	4	N/A	N/A	N/A
6/30/2017	350	6	N/A	N/A	N/A
3/31/2017	340	4	N/A	30	N/A
12/31/2016	330	7	N/A	N/A	N/A
9/30/2016	324	7	N/A	N/A	N/A
6/30/2016	314	0	N/A	N/A	N/A
3/31/2016	311	1	N/A	34	N/A
12/31/2015	311	-5	N/A	N/A	N/A
9/30/2015	315	-6	N/A	N/A	N/A
6/30/2015	308	-14	N/A	N/A	N/A
3/31/2015	302	-20	N/A	24	N/A
12/31/2014	298	-12	N/A	N/A	N/A
9/30/2014	290	-9	N/A	N/A	N/A
6/30/2014	289	1	N/A	N/A	N/A
3/31/2014	288	0	N/A	44	N/A
12/31/2013	287	4	N/A	N/A	N/A
9/30/2013	285	2	N/A	N/A	N/A
6/30/2013	289	0	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LOTUSEYEの予測収益成長が貯蓄率 ( 6.7% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: LOTUSEYEの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: LOTUSEYEの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: LOTUSEYEの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: LOTUSEYEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LOTUSEYEの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Lotus Eye Hospital and Institute 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹1.40 (vs ₹1.96 in FY 2023)

Vice President of Administration recently sold ₹173m worth of stock

Investor sentiment deteriorates as stock falls 24%

Lotus Eye Hospital and Institute Limited to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2024 earnings released: EPS: ₹0.32 (vs ₹0.56 in 3Q 2023)

Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) Price Is Out Of Tune With Earnings

Vice President of Administration recently sold ₹18m worth of stock

Second quarter 2024 earnings released: EPS: ₹0.41 (vs ₹0.43 in 2Q 2023)

Investor sentiment improves as stock rises 18%

Upcoming dividend of ₹0.50 per share at 0.6% yield

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 25, 2023

First quarter 2024 earnings released: EPS: ₹0.67 (vs ₹0.66 in 1Q 2023)

Lotus Eye Hospital and Institute Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 23%

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Vice President of Administration recently bought ₹1.7m worth of stock

Vice President of Administration recently bought ₹1.9m worth of stock

Full year 2023 earnings released: EPS: ₹1.96 (vs ₹1.44 in FY 2022)

Lotus Eye Hospital and Institute Limited Recommends Final Dividend for the Financial Year 2022-23

Investor sentiment improves as stock rises 21%

Here's Why Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Has Caught The Eye Of Investors

Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.67 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹0.43 (vs ₹0.60 in 2Q 2022)

We Ran A Stock Scan For Earnings Growth And Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Passed With Ease

Lotus Eye Hospital and Institute Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Lotus Eye Hospital and Institute's (NSE:LOTUSEYE) Dividend Will Be ₹0.50

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: EPS: ₹0.66 (vs ₹0.09 loss in 1Q 2022)

Investor sentiment improved over the past week

If EPS Growth Is Important To You, Lotus Eye Hospital and Institute (NSE:LOTUSEYE) Presents An Opportunity

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹1.44 (vs ₹0.75 in FY 2021)

Lotus Eye Hospital and Institute Limited Announces Appointment of Ramanujam Reghunathan as Chief Financial Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Lotus Eye Hospital and Institute Limited Appoints M Achuth Menon as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₹0.50 per share

First quarter 2022 earnings released: ₹0.09 loss per share (vs ₹0.32 loss in 1Q 2021)

Full year 2021 earnings released: EPS ₹0.75 (vs ₹0.51 in FY 2020)

CEO & Additional Executive Director recently bought ₹2.0m worth of stock

MD & Whole Time Director Sangeetha Sundaramoorthy Just Bought 2.8% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

MD & Whole Time Director recently bought ₹240k worth of stock

New 90-day high: ₹39.75

Lotus Eye Hospital and Institute Limited Announces Executive Appointments

Third quarter 2021 earnings released: EPS ₹0.51 (vs ₹0.08 in 3Q 2020)

Lotus Eye Hospital and Institute Limited Announces Demise of Founder Dr. S.K. Sundaramoorthy

New 90-day high: ₹37.90

New 90-day high: ₹34.40

Chief Executive Officer K. Ramalingam Just Bought 122% More Shares In Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)

Chief Executive Officer recently bought ₹2.0m worth of stock

New 90-day high: ₹32.90

Insider Buying: The Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) MD & Whole Time Director Just Bought 2.8% More Shares

MD & Whole Time Director recently bought ₹198k worth of stock

Second quarter 2021 earnings released: EPS ₹0.04

Lotus Eye Hospital and Institute Limited, Annual General Meeting, Nov 28, 2020

Lotus Eye Hospital and Institute Limited to Report First Half, 2021 Results on Nov 11, 2020

Chief Executive Officer recently bought ₹229k worth of stock

The Chief Executive Officer of Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE), K. Ramalingam, Just Bought 17% More Shares

First quarter earnings released

First quarter earnings released

Why Investors Shouldn't Be Surprised By Lotus Eye Hospital and Institute Limited's (NSE:LOTUSEYE) P/E

New 90-day high - ₹35.05

Lotus Eye Hospital and Institute Limited to Report Q1, 2021 Results on Aug 31, 2020

Should You Take Comfort From Insider Transactions At Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE)?

Lotus Eye Hospital and Institute Limited (NSE:LOTUSEYE) P/E Isn't Throwing Up Surprises

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘